Immunostimulants drugs for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. anti-inflammatoty and immuno-therapy
vs. Immunostimulants drugs
vs. convalescent plasma treatment
vs. Deferred Convalescent plasma
vs. interferon
vs. IFN beta-1a
vs. inhaled interferon
vs. IFN alpha
vs. neutralizing antibody
vs. casirivimab/imdevimab (Ronapreve)
vs. antiviral and associated therapy
vs. lopinavir/ritonavir
vs. control
vs. placebo
vs. standard of care

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 5

table network network 2

display ongoing demontrated benefit only

popup

Wei, 2022

casirivimab/imdevimab (Ronapreve) vs. standard of care

COVID-19 (hospitalized or not)

Arico, 2021 2020-003872-42

IFN beta-1a vs. standard of care

COVID-19 (hospitalized or not)

Roostaei, 2021

levamisole vs. placebo

COVID-19 (hospitalized or not)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open